Bicara Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Bicara Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($36.33M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($27.39M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($27.39M) | Nov 10, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($36.85M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($36.85M) | May 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($36.85M) | Nov 10, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($17.48M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($17.05M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($17.05M) | Nov 10, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($12.51M) | May 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($12.51M) | Nov 10, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($12.51M) | Aug 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($22.85M) | Nov 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($9.29M) | Nov 12, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($7.41M) | Nov 12, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($40.68M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($32.02M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($41.79M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($20.63M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($19.75M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($15.37M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.53M) | Nov 12, 2024 |